Betting Millions Against Avant! – Electronic News
Betting Millions Against Avant! – Electronic News
Articles by Asensio.com
Cadence 4Q Growth Spurt May Show Suit Is Hurting Avant! – Dow Jones
Cadence 4Q Growth Spurt May Show Suit Is Hurting Avant! – Dow Jones
If I could love just one – Forbes
If I could love just one – Forbes
BioTime Shares Off Again as Hextend Trial Is Debated – Dow Jones
BioTime Shares Off Again as Hextend Trial Is Debated – Dow Jones
BioTime Strong Sell Recommendation Published in Forbes.
Asensio & Company, Inc.’s strong sell recommendation was published in the January 26, 1998 issue of Forbes in the Money & Investments section. The recommendation was given based on the opinion that the Company has […]
CellularVision USA Up 17% On upcoming FCC Auction – Dow Jones
CellularVision USA Up 17% On upcoming FCC Auction – Dow Jones
Good Investment or bad? – Pensions and Investments
Good Investment or bad? – Pensions and Investments
Cadence reports large increase in place and route transition.
Cadence Design Systems, Inc. (NYSE Symbol: CDN) reported that its Deep Submicron Business Unit’s place and route products produced excellent results in the fourth quarter. Cadence does not know of any place and route benchmark […]
Investor fires on Fidelity buy – Boston Herald
Investor fires on Fidelity buy – Boston Herald
Selling short holds risks – Boston Herald
Selling short holds risks – Boston Herald
Beth Healey Boston Herald 1/7/98
Manuel Asensio, a New York short-seller […] is taking on the granddaddy of stock buyers: Fidelity Investments. Beth Healey, Boston Herald
Investor fires on Fidelity buy 1/7/98
[Asensio is] No poster boy for subtlety Beth Healy, Boston Herald
Avant! Announced No Incremental Revenue Increase
On Monday, Avant! Corporation (OTC Symbol: AVNT) (Price: $18.5625) announced two “multi-year contracts”. Avant! did not mention whether the contracts, or any small portion of the contracts, constituted any new or incremental business. Avant! claims […]
How to soar with fallen stocks – BusinessWeek
How to soar with fallen stocks – BusinessWeek
Avant! analyst fails to disclose conflict of interest.
Wessels, Arnold & Henderson, L.L.C. (“Wessels”) has issued a buy recommendation on Avant! Corporation (OTC Symbol: AVNT) (Price: $19.125) stock without disclosing that it has an interest in Avant!’s acquisition of Technology Modeling Associates, Inc. […]
Solv-Ex dissolves – The Financial Post
Solv-Ex dissolves – The Financial Post
Wessels, Arnold publishes erroneous report.
Wessels, Arnold & Henderson, L.L.C (“Wessels”) issued a report dated December 22, 1997 stating as fact that U.S Judge Ronald M. Whyte “denied Cadence’s (NYSE Symbol: CDN) motion to grant an injunction against Aquarius without […]
Aquarius injunction is imminent.
The Appeal Court instructed Judge Whyte to enter a Court Order preventing Avant! (OTC Symbol: AVNT) (Price: $17.9375) from selling its ArcCell products. The Appeal Court did not instruct Judge Whyte to enter an order […]
Court rules against Avant! on Aquarius and Apollo.
Avant! Corporation (OTC Symbol: AVNT) (Price: $17.9375) issued a press release on December 19, 1997 announcing that it is the subject of a United States District Court preliminary injunction order (“Order”). Avant!’s release states that […]
Avant! suffers series of negative litigation developments.
A hearing was held in the Avant! (OTC Symbol: AVNT) (Price: $16.75) Civil litigation last Friday, December 12, 1997 in U.S. District Court in San Jose, California. Judge Ronald M. Whyte held the hearing to […]
Zonagen down 11% in sympathy with competitor Vivus – Dow Jones
Zonagen down 11% in sympathy with competitor Vivus – Dow Jones
Zonagen feuds with short seller – Houston Business Journal
Zonagen feuds with short seller – Houston Business Journal
Jennifer Darwin Houston Business Journal 11/30/97
Despite signing a lucrative marketing deal with a major pharmaceutical company, Zonagen has seen its stock price tumble 25% over the last two weeks after receiving a negative report from a short seller [Asensio]. Jennifer […]
Jennifer Darwin Houston Business Journal 11/30/97
The people at Schering-Plough have forgotten more about drug development and regulatory strategy that this guy Asensio will ever know. [Schering failed to get Vasomax approved and lost its entire investment.] Jennifer Darwin, Houston Business […]
What if? — Is it “Hype” Or “Vision” – The Weekly Interpreter
What if? — Is it “Hype” Or “Vision” – The Weekly Interpreter
John Westergaard The Weekly Interpreter
Asensio’s work is well-reputed. John Westergaard The Weekly Interpreter
Is the Internet the medium for the self-fulfilling prophecy? – Westergaard Online
Is the Internet the medium for the self-fulfilling prophecy? – Westergaard Online
Buyer beware with this high-flier – MSNBC
Buyer beware with this high-flier – MSNBC
Schering-Plough to Sell Impotence Drug – The Wall Street Journal
Schering-Plough to Sell Impotence Drug – The Wall Street Journal
Avant!’s DRC market share grossly overstated.
Based on Dataquest’s published market statistics dated September 1997 Cadence Design Systems, Inc.’s (NYSE Symbol: CDN) share of last year’s $94.7 million Design Rule Checking (“DRC”) market was greater than 50%. Both Cadence and Mentor […]